Skip to main content

Drug Interaction Report

1 potential interaction and/or warning found for the following 2 drugs:

Filter by interaction and/or warning

Interactions between your drugs

Moderate

sulfaSALAzine fosphenytoin

Applies to: sulfasalazine, fosphenytoin

MONITOR: Some sulfonamides may inhibit the hepatic metabolism of hydantoins. Serum hydantoin levels and risk of toxicity may be increased. Data are available for sulfadiazine, sulfaphenazole, and sulfamethizole.

MANAGEMENT: Monitoring for clinical and laboratory evidence of altered efficacy and safety is recommended. Hydantoin dosage adjustments or an alternate antimicrobial may be required if an interaction is suspected. Patients should be advised to notify their physician if they experience symptoms of hydantoin toxicity (e.g., drowsiness, visual disturbances, change in mental status, seizures, nausea, or ataxia).

References (2)
  1. Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen JM (1975) "Sulfamethizole-induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism." Clin Pharmacol Ther, 17, p. 731-4
  2. Hansen JM, Kampmann JP, Siersback-Nielsen K, et al. (1979) "The effect of different sulfonamides on phenytoin metabolism in man." Acta Med Scand Suppl, 624, p. 106-10

Drug and food interactions

No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No duplication warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

See also:

Learn more

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.